Sugi Predict

Sugi Predict / Compounds / SCHEMBL629923

SCHEMBL629923

SCHEMBL629923

COC(=O)c1ccc(B(O)O)c(N)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 9/20 0.64
▸ MAPT P10636 9/20 0.64
▸ ALDH1A1 P00352 8/20 0.64
▸ HPGD P15428 7/20 0.64
▸ GAA P10253 4/20 0.64
▸ HSD17B10 Q99714 4/20 0.64
▸ GLA P06280 1/20 0.64
▸ CASP1 P29466 1/20 0.64
▸ CASP7 P55210 1/20 0.64
▸ ATM Q13315 1/20 0.64
▸ NPC1 O15118 3/20 0.55
▸ RAB9A P51151 2/20 0.55
▸ NPSR1 Q6W5P4 2/20 0.55
▸ SMN1; SMN2 Q16637 2/20 0.55
▸ USP2 O75604 1/20 0.54
▸ LMNA P02545 3/20 0.50
▸ CA1 P00915 3/20 0.50
▸ CA2 P00918 3/20 0.50
▸ L3MBTL1 Q9Y468 2/20 0.50
▸ CA12 O43570 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29957691 1.00 KDM4E (0.64) KDM4EMAPTALDH1A1HPGDGAA
Hydrochloric Acid SCHEMBL29952442 0.98 KDM4E (0.62) KDM4EMAPTALDH1A1HPGDGAA
Hydrochloric Acid SCHEMBL629029 0.98 KDM4E (0.62) KDM4EMAPTALDH1A1HPGDGAA
SCHEMBL14690961 0.86 KDM4E (0.59) KDM4EMAPTALDH1A1HPGDGAA
SCHEMBL1459513 0.81 ALOX15 (0.49) KDM4EMAPTALDH1A1HPGDGAA
SCHEMBL192100 0.81 KDM4E (0.72) KDM4EMAPTALDH1A1HPGDGAA
SCHEMBL29375113 0.81 KDM4E (0.72) KDM4EMAPTALDH1A1HPGDGAA
Hydrochloric Acid SCHEMBL29952182 0.80 LMNA (0.56) KDM4EMAPTALDH1A1GAAHSD17B10
SCHEMBL29690141 0.80 TDP1 (0.52) KDM4EMAPTALDH1A1HPGDGAA
SCHEMBL14829748 0.80 KDM4E (0.56) KDM4EMAPTALDH1A1HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4617272-A1 FUSED BICYCLIC COMPOUND Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2025-09-17 — — EP disclosed
EP-4584265-A1 NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF Cambridge Enterprise Limited (GB) 2025-07-16 — — EP disclosed
EP-4584267-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS Cambridge Enterprise Limited (GB) 2025-07-16 — — EP disclosed
US-20250215013-A1 SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF IMPACT THERAPEUTICS (SHANGHAI), INC. (CN) 2025-07-03 — — US disclosed
EP-4490161-A1 SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF Impact Therapeutics (Shanghai), Inc. (CN) 2025-01-15 — — EP disclosed
WO-2024255697-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND MEDICAL USE THEREOF 中国医药研究开发中心有限公司 2024-12-19 — — WO disclosed
US-20240368169-A1 SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF IMPACT THERAPEUTICS (SHANGHAI), INC. (CN) 2024-11-07 — — US disclosed
CN-117980307-A Substituted tricyclic compounds as PARP inhibitors and application thereof 上海瑛派药业有限公司 2024-05-03 — — CN disclosed
WO-2024052692-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-03-14 — — WO disclosed
WO-2024052690-A1 NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-03-14 — — WO disclosed
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-04-23 — — US disclosed
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-04-23 — — US disclosed
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-04-23 — — US disclosed
US-20090093465-A1 THERAPEUTIC KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-04-09 — — US disclosed
US-20090093465-A1 THERAPEUTIC KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-04-09 — — US disclosed
US-20090093465-A1 THERAPEUTIC KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-04-09 — — US disclosed
EP-1951053-A2 CETP INHIBITORS Merck & Co., Inc. (US) 2008-08-06 — — EP disclosed
WO-2008028168-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2008-03-06 — — WO disclosed
WO-2008028168-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2008-03-06 — — WO disclosed
WO-2007047591-A2 CETP INHIBITORS MERCK & CO., INC. (US) 2007-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368169-A1 SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF PARP1, PARP2, PARP11 KDM4E 2747/4885MAPT 3110/4885ALDH1A1 357/4885
US-20250215013-A1 SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF PARP1, PARP2, PARP3 KDM4E 1608/4885MAPT 3973/4885ALDH1A1 464/4885
US-20090093465-A1 THERAPEUTIC KINASE MODULATORS PACSIN2, CKS1B, CSNK1A1 KDM4E 877/4885MAPT 1743/4885ALDH1A1 4513/4885
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS PACSIN2, TNKS, PARP1 KDM4E 1151/4885MAPT 1369/4885ALDH1A1 3529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.